Evidence map›Paper›PMID 42390624›Full record

ArticleJournal of cardiovascular translational research2026

ChemoCardioNet: An Explainable Multimodal Transformer for Early Prediction of Chemotherapy-Induced Cardiotoxicity.

Sarada Prasad Dakua

Abstract read
In one paragraph

Article in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Sarada Prasad DakuaDepartment of Surgery, Hamad Medical Corporation, 3050, Doha, Qatar. sarada@iitg.ac.in.ORCID 0000-0003-2979-0272

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy-induced cardiotoxicity (CIC) remains a major cause of morbidity and mortality among cancer survivors, and conventional monitoring often fails to detect early subclinical cardiac injury. We propose ChemoCardioNet, an explainable multimodal deep learning framework that predicts cardiotoxicity risk before clinical manifestation by integrating electrocardiograms (ECG), echocardiography, clinical variables, and serum biomarkers. The architecture combines modality-specific encoders, including 1D convolutional transformers for ECG sequences, CNN-ViT hybrid blocks for echocardiographic frames, and multilayer perceptrons for clinical and biomarker features. A cross-attention fusion transformer aligns latent representations across modalities and captures temporal evolution across chemotherapy cycles. The model outputs a probabilistic cardiotoxicity risk score with feature-level explainability using SHAP analysis. In a cohort of 1,200 patients, ChemoCardioNet achieved an AUC of 0.92, outperforming single-modality and traditional machine learning approaches by 8-12%. The model predicted cardiotoxicity approximately two cycles before detectable echocardiographic dysfunction, supporting earlier risk identification and improved cardio-oncology monitoring.

Indexed as

Antineoplastic AgentsDeep LearningHeart DiseasesBiomarkersCardiotoxicityConvolutional Neural NetworksEarly DiagnosisEchocardiographyElectrocardiographyHumansPredictive Learning ModelsPredictive Value of TestsRisk AssessmentRisk FactorsTime FactorsAntineoplastic AgentsBiomarkersBiomarkerChemotherapy-induced cardiotoxicityFeature selectionInterpretabilityMachine learning

Identifiers

PMID42390624
PMCPMC13328215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.